On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab. For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab.
For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
Posted on 11/14/2025
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
